NIOX.LSE NIOX Group PLC
- Market cap
- GBX 261M
- P/E
- 32.2x
- P/B
- 4.08x
- ROE
- 35.7%
- Dividend yield
- 2.33%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is NIOX.LSE undervalued?
Graham numberNIOX.LSE trades 141.7% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
NIOX Group PLC fundamental analysis
No fundamental analysis for NIOX Group PLC yet.
NIOX Group PLC stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About NIOX Group PLC
NIOX Group Plc engages in the design, development, and commercialization of medical devices for the diagnosis, monitoring, and management of asthma and COPD worldwide. The company offers NIOX VERO, a non-invasive and point-of-care system that comprises a small portable device, sensors, individual disposable mouthpieces, and breathing handles for the measurement of fractional exhaled nitric oxide (FeNO) level in patients. The company was formerly known as Circassia Group Plc …
Full company profileNIOX Group PLC financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
NIOX Group PLC annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 23.1M | 46.3M | 48.3M | 34.6M | 23.9M | 27.9M | 31.3M | 36.8M | 41.8M | 48.7M | 96.0M |
| Gross Profit | 15.1M | 36.3M | 39.4M | 25.5M | 16.3M | 19.0M | 22.2M | 26.5M | 30.2M | 29.6M | 58.8M |
| Operating Income | -43.8M | -82.2M | -40.4M | -63.8M | -17.3M | -4.30M | 1.80M | 4.60M | 7.70M | 10.7M | 22.0M |
| EBITDA | -33.4M | -66.6M | -39.5M | -12.1M | -9.10M | 3.10M | 15.2M | 8.60M | 12.2M | 14.8M | 31.2M |
| Net Income | -137M | -99.1M | -117M | -48.3M | -33.5M | 3.60M | 16.1M | 10.7M | 3.70M | 7.00M | 23.6M |
| EPS | -0.48 | -0.31 | -0.34 | -0.13 | -0.09 | 0.01 | 0.04 | 0.02 | 0.01 | 0.02 | 0.06 |
| Balance Sheet | |||||||||||
| Total Assets | 334M | 402M | 307M | 247M | 103M | 86.4M | 98.5M | 91.5M | 68.4M | 76.2M | 73.1M |
| Total Liabilities | 21.5M | 30.8M | 124M | 162M | 37.0M | 19.6M | 16.6M | 7.70M | 8.90M | 8.60M | 7.00M |
| Shareholders' Equity | 281M | 225M | 126M | 84.8M | 66.1M | 66.8M | 81.9M | 83.8M | 59.5M | 73.7M | 66.1M |
| Cash & Short-term Investments | 117M | 59.5M | 40.7M | 27.0M | 7.40M | 12.6M | 19.4M | 19.9M | 10.9M | 19.9M | 16.8M |
| Total Debt | - | - | - | 111M | 1.60M | 1.30M | 1.00M | 1.10M | 1.50M | 1.00M | 700K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -56.7M | -57.6M | -40.6M | -25.1M | -23.9M | 1.40M | 6.70M | 11.6M | 17.2M | 15.8M | 15.6M |
| Capital Expenditure | 700K | 800K | 100K | 300K | 500K | 200K | 100K | 300K | 1.00M | 200K | 0.00 |
| Free Cash Flow | -57.4M | -58.4M | -40.7M | -25.4M | -24.4M | 1.20M | 6.60M | 11.3M | 16.2M | 15.6M | 15.6M |
| Ratios | |||||||||||
| ROE | -48.9% | -44.1% | -93.0% | -57.0% | -50.7% | 5.4% | 19.7% | 12.8% | 6.2% | 9.5% | 35.7% |
| ROA | -41.1% | -24.6% | -38.1% | -19.6% | -32.5% | 4.2% | 16.3% | 11.7% | 5.4% | 9.2% | 32.3% |
| Net Profit Margin | -594.4% | -214.0% | -242.4% | -139.6% | -140.2% | 12.9% | 51.4% | 29.1% | 8.9% | 14.4% | 24.6% |
| Debt to Equity | - | - | - | 1.31x | 0.02x | 0.02x | 0.01x | 0.01x | 0.03x | 0.01x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
NIOX Group PLC dividends
- Dividend yield
- 2.33%
- Forward dividend
- 0.02 GBX
- Payout ratio
- 71.4%
- Ex-dividend date
- May 21, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | GBP 5.00M | 0.01 | 71.4% |
| 2024 | GBP 4.20M | 0.01 | 113.5% |
| 2023 | GBP 10.5M | 0.02 | 98.1% |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns NIOX Group PLC
- Insiders 21.75%
- Institutions 67.45%
- Public & others 10.79%
- Shares outstanding 405M
- Free float 330M
NIOX Group PLC company profile
- Company name
- NIOX Group PLC
- Ticker
- NIOX.LSE
- ISIN
- GB00BJVD3B28
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 97
- Fiscal year end
- December
- Address
- Magdalen Centre, Oxford, United Kingdom, OX4 4GA
- Phone
- 44 3303 309 356
- Website
- niox.com
About NIOX Group PLC
NIOX Group Plc engages in the design, development, and commercialization of medical devices for the diagnosis, monitoring, and management of asthma and COPD worldwide. The company offers NIOX VERO, a non-invasive and point-of-care system that comprises a small portable device, sensors, individual disposable mouthpieces, and breathing handles for the measurement of fractional exhaled nitric oxide (FeNO) level in patients. The company was formerly known as Circassia Group Plc and changed its name to NIOX Group Plc in September 2022. NIOX Group Plc was incorporated in 2006 and is headquartered in Oxford, the United Kingdom.
NIOX Group PLC management
5- Mr. Jonathan Charles EmmsCEO & Executive Director · born 1963
- Ms. Sarah Elizabeth DuncanCFO & Director · born 1991
- Ms. Jodie DriverGlobal Director of Human Resources
- Mr. Tom ScacciaSenior Vice President of Americas & Research Business
- Ms. Rebecca Mary Clayton-WherityGroup Operating FD & Company Secretary